An HIV protease inhibitor is Reyataz (atazanavir). Reyataz stops the body from producing more human immunodeficiency virus (HIV) cells.The drug Reyataz is used to treat AIDS, which is brought on by the virus HIV.Reyataz is not an AIDS or HIV cure.In order to better understand Reyataz, this article is meant to provide information to Welzo users.

Health Benefits

Reyataz can enhance your standard of living by

lowering the HIV infection rate in your body. This reduces your risk of contracting diseases like infections and cancer that are linked to HIV.

Increasing the blood's CD4+ cells (T cells). Your chance of contracting additional infections or cancer is lowered as a result.

assisting you in maintaining a lower viral load if you also take other HIV drugs.

Side Effects

Reyataz may have harmful side effects, such as:

The hepatitis B virus. Reyataz use can make your hepatitis B more active or worsen it if you already have it. For the rest of your life, you might require routine liver function tests and blood checks.

The hepatitis C virus. Reyataz use can make your hepatitis C more active or worsen it if you already have it. For the rest of your life, you might require routine liver function tests and blood checks.

(Buildup of lactic acid in the blood) Lactic acidosis This condition, which can cause death, can occur with or without liver issues. If you experience even mild symptoms like muscle pain or weakness, numbness or coldness in your arms and legs, difficulty breathing, stomach pain, nausea, or vomiting, a fast or uneven heartbeat, dizziness, or a feeling of extreme weakness or exhaustion, seek emergency medical attention.

kidney issues. Kidney failure brought on by Reyataz can result in death. Reyataz treatment may require periodic monitoring of your kidney function.

Reyataz can also result in less severe side effects like:

mild stomach pain, gas, diarrhea, or nausea;

nausea, headache;

worn-out feeling

depression and worry

insomnia, a sleep disorder; or

skin alterations

If any of these symptoms are severe or do not go away, let your doctor know right away:


Every 12 hours, Reyataz is typically taken with or without food.

Take Reyataz exactly as directed on the prescription label, paying close attention to the directions.

Never use this medication in amounts greater than recommended by your doctor.

Take Reyataz pills whole. You must not chew, break, crush, or open them.

Ask your doctor if you can open a Reyataz capsule and sprinkle the contents on a spoonful of applesauce if you are unable to swallow capsules. Do not chew the mixture; immediately swallow it all.


If you take any other medications, herbs, or vitamins, Reyataz may interact with them. When a substance modifies how a drug functions, there is an interaction. This could be harmful or stop the medication from working properly.

Your doctor needs to carefully monitor all of your medications to help you avoid interactions. Tell your doctor about all of the drugs, supplements, and herbs you are taking. Speak with your doctor or pharmacist to learn how this medication may interact with other medications you are taking.

Mechanism of Action

Reyataz binds to the HIV-1 protease and stops viral proteins from being cleaved, which is required for the maturation of the HIV-1 virus. Reyataz suppresses HIV-1 replication in vivo and prevents HIV-1 replication in cell culture.

Anti-protease agents, such as ritonavir

Reverse transcriptase inhibitors without nucleosides, such as efavirenz

Inhibitors of nucleoside reverse transcriptase, such as zidovudine

Several antacids, like aluminum hydroxide,


The gastrointestinal tract quickly absorbs reyataz, which reaches peak concentrations in 1-2 hours. Less than 5% of reyataz is minimally bound to plasma proteins. Following oral administration, there is an apparent volume of distribution of about 140 L. Reyataz undergoes conjugative metabolization to produce inactive metabolites. Atazanavir is metabolized primarily by the enzymes CYP3A4 and glucuronidation, according to in vitro studies. P-gp, but not BCRP, is a substrate for atazanavir. Atazanavir is primarily eliminated from the body through biliary elimination in the form of unchanged drug (57%) and conjugated metabolites (20%) in feces.